MedTrace Logo

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

NCT00003214 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-05-15

No results posted yet for this study

Summary

RATIONALE: Chemosensitizers may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug.

PURPOSE: Randomized phase III trial to study the effectiveness of chemosensitivity testing to assign treatment for patients with stage III or stage IV ovarian cancer who have undergone surgery.

Conditions

Interventions

DRUG

carboplatin

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

in vitro sensitivity-directed chemotherapy

DRUG

paclitaxel

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • O.R. Kochli, MD · Frauenspital, Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-07-31
Primary Completion
2000-04-30
Completion
2000-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003214 on ClinicalTrials.gov